Michael Makris/LinkedIn
Feb 25, 2026, 16:34
Michael Makris: Biomarin Has Decided to Withdraw Roctavian from the Market
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn:
”IMPORTANT.
Biomarin has decided to withdraw Roctavian, the only approved Haemophilia A gene therapy, from the market.
Biomarin announced several months ago that it wanted to sell Roctavian to another company, but since they failed to find a buyer, they made the decision to voluntarily withdraw Roctavian from the market.
The problem was not that this did not work, but rather that there are a lot of other highly effective choices for haemophilia A subjects available.”
Stay updated with Hemostasis Today.
-
Jul 13, 2026, 11:25Luisa Müller: Advancing Anticoagulation Strategies for VITT at ISTH 2026
-
Jul 13, 2026, 10:49Joshua Zeidner: Advancing Menin Inhibitor Therapy in MD Education AML-ALL US Focus 2026
-
Jul 13, 2026, 10:25Flora Peyvandi: A Practical Approach to ALT Elevation After Gene Therapy at ISTH 2026
-
Jul 13, 2026, 10:02Jessica Garcia: Where Science and Community Come Together at ISTH 2026
-
Jul 13, 2026, 09:46Fabrice Cognasse: Is There Such a Thing as the Perfect Platelet Product?
-
Jul 13, 2026, 09:42Cancer-Associated Arterial Thromboembolism: Redefining the Thrombotic Burden in Oncology
-
Jul 13, 2026, 05:59Connecting and Collaborating at ISTH 2026 – NNHF
-
Jul 13, 2026, 05:58Lara Monica: Back at ISTH – Looking Forward to Science and Reconnections!
-
Jul 13, 2026, 05:57Barbara Adams Krolak: Exciting Updates From the ISTH 2026 Regulatory Session